OS Therapies Incorporated
OSTX
$1.79
$0.084.68%
AMEX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 210.58% | 457.80% | 876.99% | 574.51% | 254.13% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 321.29% | 293.34% | 377.93% | 184.93% | 56.91% |
| Operating Income | -321.29% | -293.34% | -377.93% | -184.93% | -56.91% |
| Income Before Tax | -223.70% | -148.55% | -121.18% | -52.64% | -14.00% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -223.70% | -148.55% | -121.18% | -52.64% | -14.00% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -223.70% | -148.55% | -121.18% | -52.64% | -14.00% |
| EBIT | -321.29% | -293.34% | -377.93% | -184.93% | -56.91% |
| EBITDA | -316.13% | -288.66% | -375.03% | -185.21% | -56.99% |
| EPS Basic | 98.39% | -7,102.07% | -5,729.30% | -4,724.57% | -4,996.36% |
| Normalized Basic EPS | 98.39% | -7,174.48% | -5,809.71% | -4,802.96% | -5,074.04% |
| EPS Diluted | 98.39% | -7,102.07% | -5,729.30% | -4,724.57% | -4,996.36% |
| Normalized Diluted EPS | 98.39% | -7,174.48% | -5,809.71% | -4,802.96% | -5,074.04% |
| Average Basic Shares Outstanding | 305.16% | 103.25% | 122.53% | 57.90% | -11.54% |
| Average Diluted Shares Outstanding | 305.16% | 103.25% | 122.53% | 57.90% | -11.54% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |